Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.47 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859684 | 1.00 | NHERF1 (0.55) | NHERF1MCL1TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5172845 | 0.84 | NHERF1 (0.58) | NHERF1MCL1TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17526121 | 0.83 | ALDH1A1 (0.59) | MCL1TDP1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10422313 | 0.82 | NHERF1 (0.55) | NHERF1MCL1TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29539120 | 0.82 | TBXA2R (0.46) | TDP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20789180 | 0.82 | TBXA2R (0.46) | TDP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8541216 | 0.79 | TBXA2R (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL8906273 | 0.79 | GPR35 (0.50) | TDP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6110373 | 0.79 | ALDH1A1 (0.59) | NHERF1MCL1TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29353514 | 0.79 | ALDH1A1 (0.59) | NHERF1MCL1TDP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-114645068-A | Enzymatic synthesis method of aromatic amine compound | 上海合全药物研发有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-5854179-A | Sulfur-substituted phenylsulfonylureas, processes for their preparation and their use as herbicides and plant growth regulators | HOECHST SCHERING AGREVO GMBH (DE) | 1998-12-29 | — | — | US | disclosed |
| EP-0842154-A1 | SUBSTITUTED HYDRAZINOPHENYLSULFONYL UREAS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | Hoechst Schering AgrEvo GmbH (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0790984-A1 | SULPHUR-SUBSTITUTED PHENYL SULPHONYL UREAS, PROCESS FOR THEIR PRODUCTION AND USE AS HERBICIDES AND PLANT GROWTH REGULATORS | Hoechst Schering AgrEvo GmbH (DE) | 1997-08-27 | — | — | EP | disclosed |
| EP-0790985-A1 | N-ACYL-N-ALKYLAMINO PHENYL SULPHONYL UREAS WITH SULPHUR SUBSTITUENTS, PROCESS FOR THEIR PRODUCTION AND USE AS HERBICIDES AND PLANT GROWTH REGULATORS | Hoechst Schering AgrEvo GmbH (DE) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997000247-A1 | SUBSTITUTED HYDRAZINOPHENYLSULFONYL UREAS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | HOECHST SCHERING AGREVO GMBH (DE) | 1997-01-03 | — | — | WO | disclosed |
| WO-1996014304-A1 | N-ACYL-N-ALKYLAMINO PHENYL SULPHONYL UREAS WITH SULPHUR SUBSTITUENTS, PROCESS FOR THEIR PRODUCTION AND USE AS HERBICIDES AND PLANT GROWTH REGULATORS | HOECHST SCHERING AGREVO GMBH (DE) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996014303-A1 | SULPHUR-SUBSTITUTED PHENYL SULPHONYL UREAS, PROCESS FOR THEIR PRODUCTION AND USE AS HERBICIDES AND PLANT GROWTH REGULATORS | HOECHST SCHERING AGREVO GMBH (DE) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NHERF1 3747/4885MCL1 218/4885TDP1 2163/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | NHERF1 3747/4885MCL1 218/4885TDP1 2163/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NHERF1 3882/4885MCL1 68/4885TDP1 1727/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | NHERF1 3747/4885MCL1 218/4885TDP1 2163/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NHERF1 3882/4885MCL1 68/4885TDP1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.